Surgical Innovations Group plc designs, develops, manufactures, and sells devices for use in minimally invasive surgery (SI) and precision engineering markets in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Surgical Innovations Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SUN is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SUN's weekly volatility (7%) has been stable over the past year.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: SUN exceeded the UK Medical Equipment industry which returned 6.5% over the past year.
Return vs Market: SUN exceeded the UK Market which returned 27.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Surgical Innovations Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHealth Check: How Prudently Does Surgical Innovations Group (LON:SUN) Use Debt?
8 months ago | Simply Wall StHealth Check: How Prudently Does Surgical Innovations Group (LON:SUN) Use Debt?
1 year ago | Simply Wall StDid You Manage To Avoid Surgical Innovations Group's (LON:SUN) Painful 60% Share Price Drop?
Is Surgical Innovations Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: SUN (£0.03) is trading above our estimate of fair value (£0.01)
Significantly Below Fair Value: SUN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SUN is unprofitable, so we can't compare its PE Ratio to the UK Medical Equipment industry average.
PE vs Market: SUN is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SUN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SUN is good value based on its PB Ratio (2.8x) compared to the GB Medical Equipment industry average (3.7x).
How is Surgical Innovations Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Surgical Innovations Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Surgical Innovations Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SUN is currently unprofitable.
Growing Profit Margin: SUN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SUN is unprofitable, and losses have increased over the past 5 years at a rate of 52.3% per year.
Accelerating Growth: Unable to compare SUN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SUN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (13.8%).
Return on Equity
High ROE: SUN has a negative Return on Equity (-29.54%), as it is currently unprofitable.
How is Surgical Innovations Group's financial position?
Financial Position Analysis
Short Term Liabilities: SUN's short term assets (£8.7M) exceed its short term liabilities (£2.3M).
Long Term Liabilities: SUN's short term assets (£8.7M) exceed its long term liabilities (£3.0M).
Debt to Equity History and Analysis
Debt Level: SUN's debt to equity ratio (19.6%) is considered satisfactory.
Reducing Debt: SUN's debt to equity ratio has reduced from 75.6% to 19.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SUN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SUN is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 10.5% per year.
What is Surgical Innovations Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SUN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SUN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SUN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SUN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SUN's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. David John Marsh has been the Chief Executive Officer of Surgical Innovations Group plc since February 28, 2019. Mr. Marsh served as the Group Commercial Director at Surgical Innovations Group plc on t...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD246.60K) is about average for companies of similar size in the UK market ($USD338.89K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
Experienced Management: SUN's management team is considered experienced (2.2 years average tenure).
Experienced Board: SUN's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.3%.
Surgical Innovations Group plc's company bio, employee growth, exchange listings and data sources
- Name: Surgical Innovations Group plc
- Ticker: SUN
- Exchange: AIM
- Founded: 1988
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£31.249m
- Shares outstanding: 932.82m
- Website: https://www.sigroupplc.com
Number of Employees
- Surgical Innovations Group plc
- Clayton Wood House
- 6 Clayton Wood Bank
- West Yorkshire
- LS16 6QZ
- United Kingdom
Surgical Innovations Group plc designs, develops, manufactures, and sells devices for use in minimally invasive surgery (SI) and precision engineering markets in the United Kingdom, Europe, the Asia Pacifi...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 18:32|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.